"Bear so does this seem that all data will be announced all at once?"

The news release stated "Approximately two weeks after DBL, the primary endpoint and additional secondary and exploratory endpoints are expected to be announced." So yes, according to the new release it sounds like the top-line data announcement will not be limited to the primary MACE endpoint and may also include statements releated to secondary and exploratory endpoints. However, keep in mind that no numerical values, statistical values or %RRR are guaranteed to be included in any top-line data release. As pointed out before, most top-line data announcements are simply a statement as to whether the study successfully or unsuccessfully achieved the outcome, with more details coming later at full data presentation and/or publication.

"And "acute coronary syndrome" one of the 3 indications that Resverlogix will be focusing on, would this be one and the same that went on in 2015 with the Clevland clinic, "ASSURE" trial?"

The news release stated "Following a successful BETonMACE trial, the company is focusing on three initial indications – acute coronary syndrome, vascular cognitive dementia and chronic kidney disease – with an addressable market of over 12 million patients in the top 8 markets." I think this is just another way of them saying that major adverse cardiovascular event reduction in high-risk patients is one focus area for Resverlogix/apabetalone in the post BETonMACE era, but they will also be pursuing clinical programs in vascular cognitive dementia and chronic kidney disease (as well as pulmonary arterial hypertension and Fabry's disease).

BearDownAZ